溢多利(300381) - 2024 Q3 - 季度财报

Financial Performance - Revenue for Q3 2024 was CNY 211,224,167.51, a decrease of 3.52% compared to the same period last year[1]. - Net profit attributable to shareholders was CNY 1,015,245.19, down 79.64% year-on-year[1]. - Net profit after deducting non-recurring gains and losses was CNY -4,831,989.33, a decrease of 272.20% compared to the same period last year[1]. - The company recorded a net profit of CNY 43,840,738.67 for the year-to-date, representing a 129.76% increase compared to the previous year[7]. - The net profit for Q3 2024 was CNY 43,840,738.67, a significant increase from CNY 19,081,380.90 in Q3 2023, representing a growth of approximately 130.2%[16]. - The company reported a total profit of CNY 49,557,722.50 for Q3 2024, up from CNY 22,651,004.14 in Q3 2023, marking an increase of around 119.0%[16]. - Earnings per share (EPS) for Q3 2024 was CNY 0.0873, compared to CNY 0.0253 in Q3 2023, representing an increase of approximately 245.5%[16]. - The total comprehensive income for Q3 2024 was CNY 44,971,907.06, compared to CNY 17,965,058.05 in Q3 2023, reflecting an increase of approximately 150.0%[16]. Assets and Liabilities - Total assets as of September 30, 2024, were CNY 2,957,976,679.71, a decrease of 4.43% from the end of the previous year[1]. - The company's total liabilities decreased by 50.24% to CNY 37,000,000.00 due to repayment of loans during the reporting period[4]. - Total liabilities decreased to CNY 286,302,410.75 from CNY 359,786,287.09, showing a decline of about 20.4%[13]. - The total equity attributable to shareholders of the parent company increased to CNY 2,629,142,972.77 from CNY 2,614,531,882.26, reflecting a growth of approximately 0.6%[14]. - Inventory decreased to CNY 176,098,615.34 from CNY 195,721,802.07, indicating a decline of about 10%[12]. Cash Flow - Cash flow from operating activities for the year-to-date was CNY 94,221,662.63, an increase of 94.13% year-on-year[1]. - The net cash flow from operating activities increased by 94.13% to approximately CNY 94.22 million compared to the same period last year, primarily due to increased receivables from the subsidiary Shiwai Technology and reduced operating expenses[8]. - The cash flow from operating activities showed a net increase of CNY 94,221,662.63, compared to CNY 48,535,779.36 in the same period last year, reflecting an increase of approximately 94.4%[17]. - The cash and cash equivalents at the end of Q3 2024 amounted to CNY 276,053,338.73, up from CNY 159,657,415.47 at the end of Q3 2023, indicating a growth of about 73.0%[18]. - The company experienced a net cash outflow from investing activities of CNY 247,362,686.30, contrasting with a net inflow of CNY 155,804,895.99 in the previous year[17]. - Cash inflow from financing activities was CNY 315,326,622.73, a significant increase from CNY 15,150,000.00 in the previous year[18]. - The company reported a decrease in other operating cash outflows to CNY 192,169,421.67 from CNY 281,644,359.15 in the previous year, indicating a reduction of approximately 31.7%[17]. Operational Highlights - The company reported a significant increase in prepayments, up 172.00% to CNY 10,924,213.37, due to increased equipment and project payments[4]. - Other income increased by 66.15% to CNY 14,864,568.43, primarily due to government subsidies received[7]. - Total operating revenue for Q3 2024 reached CNY 608,449,754.70, a slight increase from CNY 601,404,536.26 in the same period last year, representing a growth of approximately 0.17%[15]. - Total operating costs for the same period were CNY 585,349,924.42, up from CNY 570,138,535.99, indicating an increase of about 2.1%[15]. - Research and development expenses increased to CNY 73,735,035.11 from CNY 63,823,319.35, reflecting a growth of approximately 15.5% year-over-year[15]. - The company plans to continue expanding its market presence and invest in new product development to drive future growth[15]. Acquisitions and Investments - The acquisition of a minority stake in Victory Enzymes GmbH resulted in a significant impact on financial results, with a change in consolidation method from equity to cost method[2]. - The company completed the acquisition of 49% equity in Victory Enzymes GmbH for a transaction price of €1,226,680.38, enhancing its overseas market presence[11].